美国食品与药品监督管理局(FDA)批准了Cinqair,用于年龄在18岁及以上的严重哮喘患者的维持治疗。哮喘是一种会导致肺部气道出现炎症的慢性疾病。严重哮喘发作时非常危险,甚至会危及生命,所以通常需要住院治疗。研究者们利用随机化双盲实验对该药物的安全性和有效性进行了调查。结果显示,与使用安慰剂的严重哮喘患者相比,接受Cinqair治疗的患者哮喘发作的次数有所减少,而且在研究过程中首次发作的时间也推后了。接受 The United States Food and Drug Administration (FDA) approved Cinqair for maintenance treatment in patients with severe asthma, 18 years of age and older. Asthma is a chronic condition that causes inflammation in the airways of the lungs. Severe asthma attacks are very dangerous and can even be life-threatening, so hospitalization is usually required. The researchers investigated the safety and efficacy of the drug using a randomized double-blind experiment. The results showed fewer patients had Cinqair-treated asthma attacks compared with placebo-treated patients with severe asthma, and the duration of the first attack during the study was delayed. accept